A New Med for Old HIV

August 1, 2005

Tibotec’s long-awaited, well-studied protease inhibitor (PI) TMC114 will be in expanded access this fall (www.tibotec.com will have details soon). The PI boasts a resistance pattern all its own, holding hope for those who’ve run out of PIs. Boosted with Norvir and paired with a med to which you’re not resistant—like entry inhibitor Fuzeon—it promises to lower rising viral loads. Expect FDA approval of 114 in ’06.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.poz.com/article/A-New-Med-for-Old-HIV-1997-4006